Company Overview - Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapies for rare diseases, leveraging a diversified portfolio of approved products and a clinical pipeline targeting high-need indications [6] - The company generates revenue from commercialized rare disease therapies, including Chenodal, Cholbam, and Thiola/Thiola EC, and has additional pipeline assets such as Sparsentan and TVT-058 in clinical development [8] Financial Performance - As of January 16, 2026, Travere Therapeutics' stock price was $27.87, with a market capitalization of $2.46 billion [4] - The company reported a total revenue of $435.83 million for the trailing twelve months (TTM), with a net income of -$88.54 million [4] - In the third quarter, sales of the FILSPARI drug increased by 155% year over year to $90.9 million, contributing to total revenue of $164.9 million, up from $62.9 million the previous year [10] Investment Activity - Palisades Investment Partners, LLC initiated a new position in Travere Therapeutics, acquiring 137,768 shares valued at approximately $5.26 million [2] - This new position represents 1.99% of Palisades Investment Partners' $264.72 million in reportable U.S. equity assets as of December 31, 2025 [3] - The stock price of Travere Therapeutics increased by 50.89% over the past year, outperforming the S&P 500 by 34.01 percentage points [3] Market Position and Growth Potential - Travere Therapeutics is well-positioned to address unmet medical needs in the rare disease market, supported by strategic partnerships and clinical research initiatives [6] - The company's focus on rare metabolic and renal disorders, along with the potential expansion of FILSPARI's use pending FDA approval, suggests strong growth prospects [11]

Company Performance - Halozyme reported strong third-quarter results with record revenue of $354 million, a 22% increase year over year, and earnings per share (EPS) of $1.43, up 36% from the previous year [1] - The company reduced its net long-term debt from $1.5 billion to $800 million, indicating improved fiscal health [1] Revenue Sources - The increase in revenue includes $236 million from royalty revenue, which rose by 52% compared to the same period last year, partly due to the approval of Opdivo for subcutaneous use in Europe [1][2] - Halozyme's Enhanze drug-delivery platform is utilized in 10 drugs, including major cancer therapies like Herceptin and Darzalex Faspro [3] Market Position and Strategy - Halozyme operates as a "pick-and-shovel" stock, focusing on drug-delivery systems rather than therapies, which allows for lower costs compared to many biotech firms [4] - The company is in the process of acquiring Elektrofi, a competitor with a different drug-delivery system, which may enhance its market position [4] Future Outlook - Halozyme forecasts annual revenue between $1.3 billion and $1.375 billion, representing a growth of 28% to 35%, and expects EPS to rise to between $6.10 and $6.50, an increase of at least 44% [8] - The company is well-positioned for growth due to its low debt levels and strong revenue projections, which could provide significant returns for investors [14][15] Industry Context - The biotech sector has shown signs of recovery, with the SPDR S&P Biotech ETF rising 27% in 2025, indicating a positive trend for companies like Halozyme [6] - Both Halozyme and Catalyst Pharmaceuticals are noted for their profitability and relatively low valuations compared to the sector average, suggesting potential for investment [13][14]

Group 1: Institutional Investment Activity - Arkadios Wealth Advisors increased its position in AstraZeneca by 62.6% in Q3, owning 18,205 shares valued at $1,397,000 after purchasing an additional 7,010 shares [2] - Other institutional investors also adjusted their stakes, with Chapin Davis Inc. increasing holdings by 3.3% to 3,795 shares worth $291,000, CoreCap Advisors LLC raising its position by 30.6% to 534 shares valued at $41,000, and Highline Wealth Partners LLC lifting holdings by 32.0% to 532 shares also worth $41,000 [3] - Hedge funds and institutional investors collectively own 20.35% of AstraZeneca's stock [3] Group 2: Analyst Ratings and Forecasts - Wall Street analysts have mixed ratings for AstraZeneca, with nine analysts rating it as a "Buy" and one as a "Sell," resulting in an average rating of "Moderate Buy" and a consensus target price of $95.75 [4] - Jefferies Financial Group initiated coverage with a "buy" rating, while Barclays and TD Cowen reaffirmed their "overweight" and "buy" ratings respectively [4] Group 3: Financial Performance - AstraZeneca reported Q3 earnings of $1.19 per share, exceeding the consensus estimate of $1.14 by $0.05, with revenue of $15.19 billion, up 12.0% year-over-year [6] - The company had a return on equity of 32.89% and a net margin of 16.17% [6] Group 4: Company Overview - AstraZeneca is a global biopharmaceutical company based in Cambridge, England, formed through the merger of Astra AB and Zeneca Group in 1999 [7] - The company focuses on various therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases [8]

As filed with the Securities and Exchange Commission on January 23, 2026. Registration Statement No. 333-292131 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 __________________________________ AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 __________________________________ Invea Therapeutics, Inc. (Exact name of registrant as specified in its charter) __________________________________ Delaware 2834 87-3198325 (State or other jurisdiction of in ...

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten public offering of 9,085,778 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 1,185,101 additional shares, at a price to the public of $22.15 per share. Gross proceeds from the underwritten public offering before deducting underwriting discounts and com ...

BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Presentations” in ...

RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated January 20, 2026, notifying the Company that the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(b)(1), to maintain a minimum of $2,500,000 in stockholders’ equity ...

RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated January 20, 2026, notifying the Company that the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(b)(1), to maintain a minimum of $2,500,000 in stockholders’ equity ...

Investors with a lot of money to spend have taken a bearish stance on Liquidia (NASDAQ:LQDA).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LQDA, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner spotted ...

As filed with the Securities and Exchange Commission on January 23, 2026 Registration No. 333-292085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 AIM ImmunoTech Inc. (I.R.S. Employer Identification Number) 2117 SW Highway 484 Ocala FL 34473 (352) 448-7797 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Thomas K. Equels Chief Executive Officer AIM ImmunoTech Inc. 2117 SW Highway 484 Oc ...